

The Role of Long Non-coding RNA in Solid Tumors

Guest Editors:

Dr. Sabrina Strano

Regina Elena National Cancer
Institute, Rome, Italy

Dr. Mario Ciocce

Department of Medicine,
University Campus Bio-Medico of
Rome, Rome, Italy

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors


Dear Colleagues,

Long non-coding RNAs (lncRNAs) are a class of highly conserved and tissue-specific, non-protein-coding RNAs longer than 200 nucleotides functioning in the posttranscriptional regulation of gene expression. lncRNAs may target multiple RNAs, and this ensures a high degree of stage- and state-specific modulation. Thus, these RNAs exert profound effects on homeostatic adaptation processes, in both physiological and pathological conditions. lncRNAs have recently been emerging as important modulators of cancer phenotype, becoming invaluable tools for both biomarker discovery and mechanistic studies of cancer. Key modules of tumor or initiation and progression, ranging from the acquisition of pro-metastatic features to metabolic reprogramming and chemoresistance, are among the functions of this growing family of molecules. This Topic Issue is focused on all aspects of the dynamic roles lncRNAs play in cancer progression by mediating adaptive response to stress and by fueling intratumoral heterogeneity, in response to internal and external clues.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)